HOME > LATEST

LATEST

BUSINESS Moderna Rolls Out LP.8.1-Tailored Spikevax in Japan

September 24, 2025
BUSINESS Nikon Bets 10 Billion Yen on Regenerative Medicine CDMO Push

September 22, 2025
REGULATORY Japan OKs Biosimilars of Eylea, Actemra, Simponi, Ranmark in Likely First Debut

September 22, 2025
ORGANIZATION JPMA Publishes TPP Overview to Bridge Academia and Industry: R&D Chair

September 22, 2025
BUSINESS Daiichi Sankyo’s ADC I-DXd Shows Distinct Safety Profile in SCLC: R&D Head

September 22, 2025
REGULATORY MHLW Panel Endorses Rx-to-OTC Switch of Tadalafil in Japan

September 22, 2025
BUSINESS Allergan Seeks Label Expansion for Botox Vista in Japan

September 22, 2025
BUSINESS Takeda to Ship Medicines via Wind-Powered Vessel from 2026

September 22, 2025
REGULATORY Japan Approves Pluvicto, Izervay, and Lots More; Subcutaneous Rybrevant Not on Roster

September 22, 2025
REGULATORY Amitiza, Shingrix under PMDA Safety Review

September 22, 2025
REGULATORY Japan Extends Re-Examination Period for Nurtec, Dormicum

September 22, 2025
REGULATORY Takaichi Highlights Drug Discovery as Crucial Growth Field in LDP Race

September 22, 2025
BUSINESS Nippon Shinyaku’s DMD Med Bags Orphan Status in US

September 22, 2025
BUSINESS Kisunla Uptake “as Expected” One Year after Approval, Says Lilly Japan Exec

September 19, 2025
ORGANIZATION JPMA Sets Up Multilateral Advocacy Group to Bolster Global Voice: International Affairs Chair

September 19, 2025
REGULATORY Hayashi Stresses Drug Discovery as Key Growth Field in LDP Race

September 19, 2025
BUSINESS SanBio Eyes Akuugo Label Expansion Talks with PMDA in FY2026

September 19, 2025
BUSINESS Deciphera’s Romvimza Scores EU Nod as First TGCT Therapy

September 19, 2025
BUSINESS Lilly Japan Adds Tablet Formulation for Retevmo

September 19, 2025
REGULATORY Pharmacies, Wholesalers Split on Weekend Deliveries at Chuikyo

September 18, 2025

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…